What Ebastina Cinfa Treats: Main Uses and Benefits

Ebastina Cinfa is commonly used for the symptomatic management of two key allergic domains in situations involving certain distressing symptoms. It is applied across domains where additional symptomatic support is needed, addressing groups of symptoms that may become disruptive, specifically in Allergic Rhinitis (seasonal and perennial) and Urticaria (hives).

This medicine helps address symptom clusters in Rhinitis, easing challenging manifestations like frequent sneezing, runny nose (rhinorrhea), and nasal/ocular itching that interfere with daily comfort. In Urticaria, it plays a role in managing the significant symptomatic burden of pervasive itching and the presence of skin wheals. The therapeutic benefit is providing supportive relief, which assists with maintaining functional stability by offering non-sedating support, contributing to improved day-to-day comfort when symptoms are more noticeable.

Quick Fact: Provides supportive symptomatic relief for Allergic Rhinitis and Urticaria.

Regulatory References

1. Irish Health Products Regulatory Authority

Eligibility Map: Who can and cannot use Ebastina Cinfa — Official Regulatory Information

The following information describes the official population eligibility rules for Ebastine, strictly based on government regulatory documentation (SmPC, HPRA, etc.).

Eligibility Scope

Populations for whom use is allowed (as stated in label):

• Adults and Adolescents aged 12 years and older (for rhinitis indications).
• Patients with mild to severe renal impairment or mild to moderate hepatic impairment (no dose adjustment specified).

Populations for whom use is contraindicated:

• Patients with known hypersensitivity to the active substance (Ebastine) or any of the excipients.
• Patients with severe hepatic insufficiency (for the 20 mg strength).

Age-related eligibility rules:

• Minimum approved age is 12 years; safety and efficacy have not been established in children younger than this age.

Condition-specific eligibility rules:

• The dose must not exceed 10 mg in patients with severe hepatic insufficiency.
• Caution should be exercised in patients with known QTc interval prolongation or hypokalaemia (low potassium).

Pregnancy and lactation eligibility status (if explicitly documented):

• Pregnancy: Use is preferably avoided as a precautionary measure.
• Lactation: Should not be used during the lactation period.

Eligibility Classifications (High-Level)

Eligibility severity classification (as defined in official documents):

• Contraindicated, Caution Should Be Exercised, Preferable to Avoid, Not Established.

Regulatory basis (EMA / FDA / etc.):

• Primarily based on EMA and national European competent authority SmPC documentation.

Resulting Eligibility Structure

Official eligibility statements:

• The medicine is contraindicated for known hypersensitivity to the components.
• Safety and efficacy have not been established in children under 12 years of age.
• Caution is required for patients with pre-existing conditions like QTc interval prolongation.
• Use is restricted in severe hepatic impairment, limiting the maximum dose to 10 mg.

Connection to the overall eligibility profile (2–4 sentences): The official regulatory documents define the eligibility profile by setting absolute prohibitions based on hypersensitivity, establishing a clear minimum age of 12 years, and mandating conditional use for populations with pre-existing cardiac risks. A dose restriction is applied for patients with severe hepatic impairment, while use during pregnancy and lactation is officially classified as preferably avoided or not recommended. This structure limits use based strictly on age, organ function, and cardiovascular status.

The official interaction profile for Ebastina Cinfa (Ebastine) is defined by pharmacokinetic changes and potential pharmacodynamic effects, as documented in regulatory information.

Pharmacokinetic Interactions

The drug's active metabolite, Carebastine, is primarily formed through the hepatic CYP3A4 enzyme system. Co-administration with potent CYP3A4 inhibitors, such as the antifungal medicines ketoconazole and itraconazole, and the macrolide antibiotic erythromycin, results in a pharmacokinetic interaction leading to increased plasma concentrations of Ebastine and Carebastine. Conversely, co-administration with the antituberculosis medicine rifampicin (a strong CYP inducer) results in a pharmacokinetic interaction that could lead to lower plasma concentrations and a reduced antihistamine effect.

Interaction Constraints and Cautions

• High-Risk Co-administration: Concomitant use with the macrolide antibiotics clarithromycin and josamycin is not recommended by regulatory agencies.
• Pharmacodynamic Caution: Caution is advised when Ebastine is administered with any other medicine known to prolong the QTc interval, due to an increased risk of additive cardiac effects.
• Food/Substance Interactions: Taking the medicine with food is documented to increase the plasma levels and AUC of Carebastine by approximately 1.5- to 2.0-fold, although this pharmacokinetic change does not modify its clinical effect. No interaction has been reported with alcohol, theophylline, warfarin, cimetidine, or diazepam.
• Population Note: Caution is required in patients with severe hepatic impairment due to the potential for reduced drug clearance and accumulation.

Ebastina Cinfa is a piperidine derivative that functions as a second-generation H1-receptor antagonist. The parent compound is extensively metabolized in the liver via the cytochrome P450 3A4 enzyme system to its active carboxylic acid metabolite, carebastine. The compound and its metabolite competitively bind to peripheral H1 histamine receptors, preventing the activation of these receptors by endogenous histamine. This action modulates the signaling pathway and stabilizes the H1 receptor in its inactive conformation, thereby limiting its capacity to propagate downstream cellular responses. Carebastine exhibits selective affinity for the peripheral H1 receptor, and the molecule demonstrates low penetration of the blood-brain barrier.

Official Administration Guidelines

Ebastina Cinfa is administered via the oral route, following a standardized usage protocol based on the active substance Ebastine. The administration is characterized by a once-daily regimen and flexible timing relative to food intake. The typical dosage for adults and adolescents (12 years and older) is 10 mg once a day, though it is possible to increase to a maximum of 20 mg daily for severe symptomatic requirements.

The method of administration is specific to the formulation: film-coated tablets must be swallowed whole with liquid, while the orodispersible tablets are designed to dissolve instantly on the tongue, without the need for water. A key procedural restriction is that the daily dose must not exceed 10 mg for patients with severe hepatic impairment, whereas no adjustment is specified for individuals with renal impairment. Treatment duration is guided by the persistence of symptoms, with clinical use extending up to one year.

Research Evidence / Overview of Studies for Ebastina Cinfa

This overview summarizes the type of clinical research conducted for the active ingredient, Ebastine, and what those studies have explored, according to documentation from authoritative sources. The purpose is to describe the evidence landscape in a way that is accurate and neutral, without offering clinical guidance or making claims about individual outcomes or what the medicine was studied for.

Evidence for Use in Allergic Rhinitis (Seasonal and Perennial)

Research for allergic rhinitis has focused primarily on randomized, double-blind clinical trials (RCTs); these studies examined outcomes related to the medicine. Many trials included active comparator treatments alongside the medicine to evaluate specific patterns. The populations studied were typically adults and adolescents who experience conditions characterized by fluctuating or episodic manifestations.

Studies monitored outcomes related to physical discomfort, such as changes in nasal and ocular symptom scores. Trials were often conducted over short-term periods of two to four weeks, with some extending to intermediate durations of up to 12 weeks. Findings describe patterns observed in the studies where measured outcomes evolved in the populations receiving the medicine, and research also explored whether the medicine was associated with outcomes reflecting daily functioning or activity level.

Comparative evidence is lacking for certain long-term scenarios. While studies compared the medicine to various other treatments, findings were mixed regarding specific performance across all compared second-generation antihistamines on every measured symptom. The results apply only to the populations studied and the specific conditions of the trials.

Evidence for Use in Chronic Urticaria (Hives)

For chronic urticaria (hives), the research landscape similarly involves randomized, controlled clinical trials exploring conditions associated with acute or disruptive episodes on the skin. Research has focused on adult populations, and the studies monitored outcomes capturing phases of heightened symptom activity.

Study outcomes examined were patient-reported measures of disease activity, including the intensity of itching (pruritus) and the number and size of wheals. Studies report how symptoms evolved in the observed populations when using the medicine, and this body of evidence contributes to the broader evidence landscape regarding how these skin conditions where symptoms may vary in intensity are assessed.

A research limitation is that the primary studies focused on chronic spontaneous urticaria, and often did not include patients with less common types of urticaria or angio-oedema occurring alone, meaning data for certain groups remain insufficient.

Overview of Long-Term Studies and Extended Follow-up

Research has explored patterns associated with the medicine beyond the initial few weeks of treatment. Some trials included follow-up periods that extended for up to 12 weeks, and for urticaria, some studies monitored patient responses over periods up to one year. This extended research provided insight into short-term changes that may occur with continuous use.

However, a consistent observation across regulatory summaries is that long-term effects are not fully established through extensive comparative studies. Follow-up durations were limited in many key trials, meaning that data related to the durability of the measured effect over many consecutive seasons or years remain insufficient.

What is Still Uncertain in the Research Record

The evidence landscape highlights specific questions where data are either limited or still emerging. Evidence quality varies across studies, particularly when looking at specific subgroup outcomes or comparisons between multiple treatments.

Key areas of uncertainty include comparative evidence lacking that definitively assesses the medicine against other treatments over continuous periods longer than three months, and limited information about measured outcomes in very specific patient subgroups. Findings from trials exploring short-term symptom changes do not determine whether an individual will respond similarly outside the specific, controlled conditions under which the studies were conducted.

Key Studies & References

1. Public Assessment Report Scientific discussion Notaxo 10 mg and 20 mg, orodispersible tablets (ebastine) NL/H (Used for regulatory context, indications, and general evidence overview)

Common questions about Ebastina Cinfa (FAQ)

Q: How long does the effect of one dose of Ebastina Cinfa last?

Studies and official product information indicate that the antihistamine effect of the medicine begins within one hour of administration. This effect has been shown to last for more than 24 hours, which supports the medicine's once-daily regimen as detailed in the regulatory guidelines.

Q: Is Ebastina Cinfa the same type of medicine as cetirizine or loratadine?

According to official documents, the active substance, ebastine, is classified as a second-generation H1-receptor antagonist. This pharmacological class includes other common allergy medicines, such as cetirizine and loratadine. These medicines are often used as active comparators in clinical studies that examine ebastine’s patterns of effect.

Q: Can Ebastina Cinfa be used alongside medicines for stomach acid or heartburn?

Official regulatory documents define potential interactions with other medicines. For the stomach acid medicine cimetidine, no interaction has been reported between this compound and the active substance in Ebastina Cinfa. This information helps define the safety profile when taken with certain other medications.

Q: What kind of allergic rhinitis does Ebastina Cinfa treat (seasonal, perennial, or both)?

The medicine is indicated for the symptomatic treatment of allergic rhinitis. Official product information confirms that this indication covers both seasonal (occurring at specific times of the year) and perennial (occurring year-round) allergic rhinitis.

Q: Can Ebastina Cinfa affect liver enzymes?

Abnormal changes in liver function tests have been reported as a rare adverse reaction. These changes include results for enzymes such as transaminases, gamma-GT, and alkaline phosphatase. Regulatory documents classify these events as part of the rare hepatobiliary disorders.

Q: Why is caution advised for patients with low blood potassium levels (hypokalaemia)?

Caution is officially advised for patients who have hypokalaemia, which is the term for low blood potassium. This is because hypokalaemia is a recognized risk factor in individuals who are at cardiac risk or who have pre-existing QTc interval prolongation (an alteration in heart rhythm activity).

Q: Is it true that Ebastina Cinfa should not be used for an acute allergic emergency?

The medicine is officially indicated for the symptomatic treatment of chronic conditions, specifically allergic rhinitis and chronic urticaria (hives). Its use is not indicated for the management of acute or sudden allergic emergencies.

Q: What should be done if a dose of Ebastina Cinfa is forgotten?

The official product information addresses procedures for missed doses. It typically advises taking a missed dose as soon as possible, unless it is close to the next scheduled dose, in which case the missed dose is usually skipped. The instructions state that two doses should never be taken at one time.

Q: Can Ebastina Cinfa affect the results of a skin allergy test?

Official documents describe the medicine's activity as inhibiting the histamine-induced wheal, which is the basis of skin allergy testing. Because of this antihistamine action, the medicine may affect the accuracy of the results for these tests.

Q: Can older adults use Ebastina Cinfa without dose changes?

Studies examining the pharmacokinetics (how the body processes the drug) in elderly subjects showed no statistically significant changes compared to those in young adult volunteers. Studies in this population did not show a need for a specific dose adjustment based solely on age.

Q: Does Ebastina Cinfa affect a person's ability to drive or use machinery?

Official product information states that at the recommended therapeutic doses, the medicine does not affect a person's ability to drive or operate machines. However, caution is advised, as some sensitive subjects may still experience drowsiness (somnolence) or dizziness.

Q: What ingredients other than Ebastine are in Ebastina Cinfa tablets?

In addition to the active substance, ebastine, the tablets contain various inactive ingredients called excipients. These can include substances like lactose monohydrate and aspartame, which is listed as a source of phenylalanine.

Q: Does Ebastina Cinfa have a risk of becoming habit-forming?

The official regulatory information that defines the medicine’s safety profile does not list the risk of dependence or habit formation among the special warnings or adverse effects associated with the medicine.

Q: Is a nosebleed considered a common or rare side effect of Ebastina Cinfa?

Official safety classifications list epistaxis (the medical term for a nosebleed) as an uncommon adverse reaction. This categorization means it is reported in less than 1 out of 100 people but more than 1 out of 1,000 people.

Q: What is the significance of the tablet having a score line?

While some film-coated tablet formulations may feature a score line, the official administration instructions require the tablet to be swallowed whole with liquid. The fact that the instructions require swallowing the tablet whole indicates the score line is not intended for dividing the dose.

Q: Does taking Ebastina Cinfa affect the menstrual cycle?

In the safety classification, menstrual pain has been listed as a rare adverse reaction. This is based on reports collected during clinical trials and post-marketing surveillance, and it is part of the documented safety information.

Q: What level of protein binding does Ebastine have in the blood?

The official pharmacokinetic properties describe the distribution of the active substance in the body. Both ebastine and its active metabolite, carebastine, are classified as highly protein bound in the blood, at a level greater than 97%.

Ebastina Cinfa tablets do not require special temperature conditions for storage, but they must be kept out of the sight and reach of children. The medicine should not be used after the expiration date printed on the packaging.

For disposal, unused or expired medication, along with the packaging, must be deposited at a designated pharmacy collection point (like a SIGRE point in Spain). If a take-back program is unavailable and no specific flushing instructions are provided for the drug, the medicine may be mixed with an undesirable substance, placed in a sealed container, and thrown in the household trash to prevent accidental ingestion.